litlas
Log inCreate account

Robert I. Haddad

Active 2003–2026

168
Papers
35,054
Citations
91
h-index
157
i10-index

Citations

Citations per year for Robert I. Haddad1964: 1 citations1976: 1 citations1995: 2 citations1999: 1 citations2001: 1 citations2002: 1 citations2003: 1 citations2004: 5 citations2005: 3 citations2006: 22 citations2007: 17 citations2008: 42 citations2009: 74 citations2010: 74 citations2011: 99 citations2012: 98 citations2013: 121 citations2014: 133 citations2015: 158 citations2016: 185 citations2017: 326 citations2018: 336 citations2019: 1,266 citations2020: 1,477 citations2021: 1,603 citations2022: 1,404 citations2023: 1,101 citations2024: 1,792 citations2025: 908 citations2026: 26 citations1965–1975: no citations, so these years are not shown1977–1994: no citations, so these years are not shown1996–1998: no citations, so these years are not shown2000: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,273 citing papers, 25.9% of this breakdownChina: 1,921 citing papers, 15.2% of this breakdownItaly: 636 citing papers, 5% of this breakdownGermany: 604 citing papers, 4.8% of this breakdownUnited Kingdom: 541 citing papers, 4.3% of this breakdownJapan: 513 citing papers, 4.1% of this breakdownFrance: 498 citing papers, 4% of this breakdownCanada: 416 citing papers, 3.3% of this breakdownSpain: 319 citing papers, 2.5% of this breakdownNetherlands: 303 citing papers, 2.4% of this breakdownAustralia: 296 citing papers, 2.3% of this breakdownIndia: 275 citing papers, 2.2% of this breakdown
0%25.9%Other 24%

Institutions

Fields

  • Medicine74.2%
  • Biochemistry, Genetics and Molecular Biology16.3%
  • Immunology and Microbiology4.7%
  • Dentistry1%
  • Engineering0.9%
  • Health Professions0.6%
  • Other2.3%

Topics

  • Cancer Immunotherapy and Biomarkers10.9%
  • Head and Neck Cancer Studies10.5%
  • Immunotherapy and Immune Responses3.2%
  • Esophageal Cancer Research and Treatment2.2%
  • Thyroid Cancer Diagnosis and Treatment2.2%
  • Lung Cancer Treatments and Mutations2.1%
  • Other68.9%

Coauthors

All papers

Open in search
  1. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

    Authors: Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, J. Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, William J. Geese, Justin Kopit, James W. Shaw, Maura L. Gillison - New England Journal of Medicine 2016 cited by 5,078

  2. Head and neck cancer

    Authors: Mayur D. Mody, James W. Rocco, Sue S. Yom, Robert I. Haddad, Nabil F. Saba - The Lancet 2021 cited by 822

  3. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy

    Authors: Adrienne Luoma, Shengbao Suo, Yifan Wang, Lauren Gunasti, Caroline Porter, Nancy Nabilsi, Jenny Tadros, Andrew Ferretti, Sida Liao, Cagan Gurer, Yu‐Hui Chen, Shana Criscitiello, Cora A. Ricker, Danielle Dionne, Orit Rozenblatt–Rosen, Ravindra Uppaluri, Robert I. Haddad, Orr Ashenberg, Aviv Regev, Eliezer M. Van Allen, Gavin MacBeath, Jonathan D. Schoenfeld, Kai W. Wucherpfennig - Cell 2022 cited by 392

  4. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

    Authors: Nancy Y. Lee, Robert L. Ferris, Amanda Psyrri, Robert I. Haddad, Makoto Tahara, Jean Bourhis, Kevin J. Harrington, Peter Mu‐Hsin Chang, Jin‐Ching Lin, Mohammad Razaq, Maria Margarida Teixeira, József Lövey, J. Chamois, Antonio Rueda, Chaosu Hu, Lara Dunn, Mikhail Dvorkin, Steven De Beukelaer, Dmitri Pavlov, Holger Thurm, Ezra E.W. Cohen - The Lancet Oncology 2021 cited by 617

  5. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

    Authors: David G. Pfister, Sharon Spencer, David J. Adelstein, Douglas R. Adkins, Yoshimi Anzai, David M. Brizel, Justine Y. Bruce, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, A. Dimitrios Colevas, David W. Eisele, Moon J. Fenton, Robert L. Foote, Thomas J. Galloway, Maura L. Gillison, Robert I. Haddad, Wesley L. Hicks, Ying J. Hitchcock, Antonio Jimeno, Debra S. Leizman, Ellie Maghami, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, James W. Rocco, Cristina P. Rodriguez, Jatin P. Shah, Randal S. Weber, Gregory S. Weinstein, Matthew E. Witek, Frank Worden, Sue S. Yom, Weining Zhen, Jennifer L. Burns, Susan Darlow - Journal of the National Comprehensive Cancer Network 2020 cited by 1,374

  6. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

    Authors: Robert I. Haddad, Lindsay Bischoff, Douglas W. Ball, Victor Bernet, Erik Blomain, Naifa L. Busaidy, Michael J. Campbell, Paxton V. Dickson, Quan‐Yang Duh, Hormoz Ehya, Whitney Goldner, Theresa Guo, Megan R. Haymart, Shelby Holt, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Dominick Lamonica, Susan J. Mandel, Stephanie Markovina, Bryan McIver, Christopher D. Raeburn, Rod Rezaee, John A. Ridge, Mara Y. Roth, Randall P. Scheri, Jatin P. Shah, Jennifer A. Sipos, Rebecca S. Sippel, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Michael W. Yeh, Carly J. Cassara, Susan Darlow - Journal of the National Comprehensive Cancer Network 2022 cited by 503

  7. NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022

    Authors: Jimmy J. Caudell, Maura L. Gillison, Ellie Maghami, Sharon Spencer, David G. Pfister, Douglas R. Adkins, Andrew C. Birkeland, David M. Brizel, Paul M. Busse, Anthony J. Cmelak, A. Dimitrios Colevas, David W. Eisele, Thomas J. Galloway, J.L. Geiger, Robert I. Haddad, Wesley L. Hicks, Ying J. Hitchcock, Antonio Jimeno, Debra S. Leizman, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, James W. Rocco, Cristina P. Rodriguez, P. Savvides, David A. Schwartz, Jatin P. Shah, David J. Sher, Maie A. St. John, Randal S. Weber, Gregory S. Weinstein, Frank Worden, Justine Y. Bruce, Sue S. Yom, Weining Zhen, Jennifer L. Burns, Susan Darlow - Journal of the National Comprehensive Cancer Network 2022 cited by 531

  8. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

    Authors: Robert L. Ferris, Robert I. Haddad, Caroline Even, Makoto Tahara, Mikhail Dvorkin, Tudor–Eliade Ciuleanu, Paul M. Clément, Ricard Mesı́a, С. И. Кутукова, Lyubov Zholudeva, Amaury Daste, Javier Caballero-Daroqui, Bhumsuk Keam, Ihor Vynnychenko, C. Lafond, Jagdish Shetty, Helen Mann, Jean Fan, Sophie Wildsmith, Nassim Morsli, Jérôme Fayette, Lisa Licitra - Annals of Oncology 2020 cited by 365

  9. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma

    Authors: Jonathan D. Schoenfeld, Glenn J. Hanna, Vickie Y. Jo, Bhupendra Rawal, Yu‐Hui Chen, Paul Catalano, Ana Lako, Zoe Ciantra, Jason L. Weirather, Shana Criscitiello, Adrienne Luoma, Nicole G. Chau, Jochen H. Lorch, Jason Kass, Donald J. Annino, Laura A. Goguen, Anupam M. Desai, Brendan Ross, Hina Shah, Heather A. Jacene, Danielle N. Margalit, Roy B. Tishler, Kai W. Wucherpfennig, Scott J. Rodig, Ravindra Uppaluri, Robert I. Haddad - JAMA Oncology 2020 cited by 347

  10. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

    Authors: Ravindra Uppaluri, Katie M. Campbell, Ann Marie Egloff, Paul Zolkind, Zachary L. Skidmore, Brian Nussenbaum, Randal C. Paniello, Jason T. Rich, Ryan S. Jackson, Patrik Pipkorn, Loren S. Michel, Jessica Ley, Peter Oppelt, Gavin P. Dunn, Erica K. Barnell, Nicholas C. Spies, Tianxiang Lin, Tiantian Li, David T. Mulder, Youstina Hanna, Iulia Cirlan, Trevor J. Pugh, Tenny Mudianto, Rachel Riley, Liye Zhou, Vickie Y. Jo, Matthew D. Stachler, Glenn J. Hanna, Jason Kass, Robert I. Haddad, Jonathan D. Schoenfeld, Evisa Gjini, Ana Lako, Wade L. Thorstad, Hiram A. Gay, Mackenzie Daly, Scott J. Rodig, Ian S. Hagemann, Dorina Kallogjeri, Jay F. Piccirillo, Rebecca D. Chernock, Malachi Griffith, Obi L. Griffith, Douglas R. Adkins - Clinical Cancer Research 2020 cited by 365

  11. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

    Authors: Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, J. Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Mark Lynch, Vijayvel Jayaprakash, Li Li, Maura L. Gillison - Oral Oncology 2018 cited by 800

  12. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

    Authors: Ranee Mehra, Tanguy Y. Seiwert, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Ravit Geva, Hyun Cheol Chung, Chia‐Chi Lin, Deepti Aurora-Garg, Archana Ray, Kumudu Pathiraja, Jonathan D. Cheng, Laura Q.M. Chow, Robert I. Haddad - British Journal of Cancer 2018 cited by 456

  13. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

    Authors: Robert I. Haddad, Kevin J. Harrington, Makoto Tahara, Robert L. Ferris, Maura L. Gillison, Jérôme Fayette, Amaury Daste, P. Koralewski, Bogdan Żurawski, Miren Taberna, Nabil F. Saba, Milena Perez Mak, Andrzej Kawecki, Gustavo Girotto, Miguel Ángel Álvarez-Avitia, Caroline Even, Joaquin Gabriel Reinoso Toledo, Alexander Guminski, Urs Müller‐Richter, Naomi Kiyota, Mustimbo Roberts, Tariq Aziz Khan, Karen Miller-Moslin, Wei Li, Athanassios Argiris - Journal of Clinical Oncology 2022 cited by 158

  14. Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer

    Authors: Giacomo Oliveira, Ann Marie Egloff, Alexander B. Afeyan, Jacquelyn O. Wolff, Zexiang Zeng, Rebecca D. Chernock, Liye Zhou, Cameron Messier, Patrick H. Lizotte, Kathleen L. Pfaff, Kari Stromhaug, Livius Penter, Robert I. Haddad, Glenn J. Hanna, Jonathan D. Schoenfeld, Laura A. Goguen, Donald J. Annino, Vickie Y. Jo, Peter Oppelt, Patrik Pipkorn, Ryan S. Jackson, Sidharth V. Puram, Randal C. Paniello, Jason T. Rich, J. C. Webb, José P. Zevallos, Mena Mansour, Jingxin Fu, Gavin P. Dunn, Scott J. Rodig, Jessica Ley, Luc G.T. Morris, Lara Dunn, Cloud P. Paweletz, Dorina Kallogjeri, Jay F. Piccirillo, Douglas R. Adkins, Catherine J. Wu, Ravindra Uppaluri - Science Immunology 2023 cited by 116

  15. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

    Authors: Yu‐Pei Chen, Nofisat Ismaila, Melvin L.K. Chua, A. Dimitrios Colevas, Robert I. Haddad, Shao Hui Huang, Joseph Wee, Alexander C. Whitley, Junlin Yi, Sue S. Yom, Anthony T.�C. Chan, Chaosu Hu, Jinyi Lang, Quynh‐Thu Le, Anne W.M. Lee, Nancy Y. Lee, Jin‐Ching Lin, Brigette Ma, T. J. Morgan, Jatin P. Shah, Ying Sun, Jun Ma - Journal of Clinical Oncology 2021 cited by 391

  16. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

    Authors: Amanda Psyrri, Jérôme Fayette, Kevin J. Harrington, Maura L. Gillison, M-J. Ahn, Shunji Takahashi, Jared Weiss, J-P. Machiels, Shrujal S. Baxi, Alexander Vasilyev, А. А. Карпенко, Mikhail Dvorkin, Ching-Yun Hsieh, S.C. Thungappa, Pedro Pérez Segura, Ihor Vynnychenko, Robert I. Haddad, Stefan Kasper, P. S. Mauz, V. Baker, Philip He, Brent Evans, Sophie Wildsmith, Richard F. Olsson, Alejandro Yovine, John F. Kurland, Nassim Morsli, Tanguy Y. Seiwert - Annals of Oncology 2022 cited by 144

  17. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

    Authors: Diana Miao, Claire A. Margolis, Natalie I. Vokes, David Liu, Amaro Taylor‐Weiner, Stephanie A. Wankowicz, Dennis O. Adeegbe, Daniel Keliher, Bastian Schilling, Adam Tracy, Michael P. Manos, Nicole G. Chau, Glenn J. Hanna, Paz Polak, Scott J. Rodig, Sabina Signoretti, Lynette M. Sholl, Jeffrey A. Engelman, Gad Getz, Pasi A. Jänne, Robert I. Haddad, Toni K. Choueiri, David A. Barbie, Rizwan Haq, Mark M. Awad, Dirk Schadendorf, F. Stephen Hodi, Joaquim Bellmunt, Kwok‐Kin Wong, Peter S. Hammerman, Eliezer M. Van Allen - Nature Genetics 2018 cited by 696

  18. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

    Authors: Joshua Bauml, Tanguy Y. Seiwert, David G. Pfister, Francis P. Worden, Stephen V. Liu, Jill Gilbert, Nabil F. Saba, Jared Weiss, Lori J. Wirth, Ammar Sukari, Hyunseok Kang, Michael K. Gibson, Erminia Massarelli, Steven Powell, Amy Meister, Xinxin Shu, Jonathan D. Cheng, Robert I. Haddad - Journal of Clinical Oncology 2017 cited by 652

  19. Tipifarnib in Head and Neck Squamous Cell Carcinoma WithHRASMutations

    Authors: Alan L. Ho, Irene Braña, Robert I. Haddad, Jessica R. Bauman, Keith C. Bible, Sjoukje F. Oosting, Deborah Jean Lee Wong, Myung‐Ju Ahn, Valentina Boni, Caroline Even, Jérôme Fayette, M.J. Flor, Kevin J. Harrington, David S. Hong, Sung‐Bae Kim, Lisa Licitra, Ioanna Nixon, Nabil F. Saba, Stephan Hackenberg, Pol Specenier, Francis P. Worden, Binaifer Balsara, Mollie Leoni, Bridget Martell, Catherine Scholz, Antonio Gualberto - Journal of Clinical Oncology 2021 cited by 196

  20. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

    Authors: Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta, Amit Mahipal, Ranee Mehra, Makoto Tahara, Raanan Berger, Joseph P. Eder, Barbara Burtness, Se‐Hoon Lee, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Jared Weiss, Ravit Geva, Chia‐Chi Lin, Hyun Cheol Chung, Amy Meister, Marisa Dolled‐Filhart, Kumudu Pathiraja, Jonathan D. Cheng, Tanguy Y. Seiwert - Journal of Clinical Oncology 2016 cited by 859

  21. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck

    Authors: Glenn J. Hanna, Anne O’Neill, Kee‐Young Shin, Kristine Wong, Vickie Y. Jo, Charles T. Quinn, Jennifer M. Cutler, Michelle Flynn, Patrick H. Lizotte, Donald J. Annino, Laura A. Goguen, Jason Kass, Eleni M. Rettig, Rosh K.V. Sethi, Jochen H. Lorch, Jonathan D. Schoenfeld, Danielle N. Margalit, Roy B. Tishler, Peter C. Everett, Anupam M. Desai, Megan E. Cavanaugh, Cloud P. Paweletz, Ann Marie Egloff, Ravindra Uppaluri, Robert I. Haddad - Clinical Cancer Research 2021 cited by 103

  22. Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

    Authors: Kevin J. Harrington, Robert L. Ferris, Maura L. Gillison, Makoto Tahara, A. Argiris, Jérôme Fayette, Michael Schenker, Åse Bratland, John Walker, Peter Grell, Caroline Even, Christine H. Chung, Rebecca Redman, Alexandre Coutté, Sébastien Salas, Clíona Grant, Sérgio de Azevedo, Denis Soulières, Aaron R. Hansen, Wei Li, Tariq Aziz Khan, Karen Miller-Moslin, Mustimbo Roberts, Robert I. Haddad - JAMA Oncology 2023 cited by 72

  23. Frameshift events predict anti–PD-1/L1 response in head and neck cancer

    Authors: Glenn J. Hanna, Patrick H. Lizotte, Megan E. Cavanaugh, Frank C. Kuo, Priyanka Shivdasani, Alexander Frieden, Nicole G. Chau, Jonathan D. Schoenfeld, Jochen H. Lorch, Ravindra Uppaluri, Laura E. MacConaill, Robert I. Haddad - JCI Insight 2018 cited by 279

  24. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors

    Authors: Amin H. Nassar, Elio Adib, Sarah Abou Alaiwi, Talal El Zarif, Stefan Groha, Elie W. Akl, Pier Vitale Nuzzo, Tarek H. Mouhieddine, Tomin Perea-Chamblee, Kodi Taraszka, Habib El‐Khoury, Muhieddine Labban, Christopher J. Fong, Kanika Arora, Chris Labaki, Wenxin Xu, Guru Sonpavde, Robert I. Haddad, Kent W. Mouw, Marios Giannakis, F. Stephen Hodi, Noah Zaitlen, Adam J. Schoenfeld, Nikolaus Schultz, Michael F. Berger, Laura E. MacConaill, Guruprasad Ananda, David J. Kwiatkowski, Toni K. Choueiri, Deborah Schrag, Jian Carrot‐Zhang, Alexander Gusev - Cancer Cell 2022 cited by 116